A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
抗 LAG-3 抗体 favezelimab 联合 pembrolizumab 治疗经治晚期微卫星稳定性结直肠癌的首次人体研究
期刊:ESMO Open
影响因子:7.1
doi:10.1016/j.esmoop.2022.100639
E Garralda, A Sukari, N J Lakhani, A Patnaik, Y Lou, S-A Im, T Golan, R Geva, M Wermke, M de Miguel, J Palcza, S Jha, M Chaney, A K Abraham, J Healy, G S Falchook2